Companies

Otsuka Pharmaceutical

Mentioned in 1 analyzed podcast episode across 1 show

Episode Mentions

Pharma and BioTech Daily

Pharma and BioTech Daily · Jul 28, 2026

AstraZeneca's $80B Target Amid Setbacks? | Pharma and Biotech Daily

FDA approved Symtrio, first-in-class NDSRI non-stimulant treatment for ADHD

Antibody-Drug Conjugates (ADCs) in OncologyNon-Stimulant ADHD TherapeuticsDuchenne Muscular Dystrophy (DMD) Treatments
View Analysis